Compass Therapeutics (CMPX) 2025 Conference June 05, 2025 11:05 AM ET Speaker0 And one of the biotech analysts at Jefferies. It's with great pleasure I'd like to welcome Tom Schutz, the CEO of Compass Therapeutics. Thanks so much for joining us today, Tom. Speaker1 Thanks, Maury. Thanks for inviting us. Appreciate it. Speaker0 And we're gonna do fireside chat format. So maybe for those who are new to this story, if you can give a one minute intro to Compass. Speaker1 Sure, thanks. Compass, we're based in Bo ...

Financial Data and Key Metrics Changes - The company reported a significant increase in the overall response rate for its lead drug, tevesimig, in the second line biliary tract cancer study, with a response rate of 17.1% compared to 5.3% for the control arm, indicating a more than tripling of the response rate [12][13] - The study also showed a statistically significant difference with a p-value of 0.031, highlighting the drug's efficacy [13] Business Line Data and Key Metrics Changes - The lead program, tevesimig, is a bispecific antibody targeting DLL4 and VEGF A, which has shown promising results in clinical trials [4][7] - The company is also advancing CTX-471, a monoclonal antibody agonist targeting CD137, which has shown a 28% response rate in a post-PD-1 patient population [22][23] Market Data and Key Metrics Changes - The company identified a significant unmet medical need in the second line biliary tract cancer market, where there are currently no labeled therapies for the majority of patients [11] - The basket study for tevesimig in DLL4 positive cancers is expected to explore a range of solid tumor indications, indicating a broad market opportunity [19] Company Strategy and Development Direction - The company aims to leverage its unique StitchMaps platform to develop next-generation antibody therapeutics, focusing on dual blockade strategies to enhance efficacy in oncology [3][7] - Future plans include a Phase II basket study for tevesimig and potential label expansion studies following its approval [19] Management's Comments on Operating Environment and Future Outlook - Management expressed enthusiasm about the upcoming readouts for progression-free survival and overall survival, indicating a positive outlook for tevesimig's clinical development [17] - The company is optimistic about the performance of the control arm in clinical trials, suggesting a potential treatment effect that could lead to fewer deaths than initially expected [17] Other Important Information - The company has fast track status for tevesimig, which could expedite its approval process, with potential approval in the second half of 2026 [19][32] - The company is also developing CTX-8371, a PD-1 PD-L1 bispecific antibody, which is currently in Phase I studies and is expected to present clinical data in the second half of the year [29] Q&A Session Summary Question: Can you provide an overview of tevesimig's clinical data? - The overall response rate for tevesimig plus paclitaxel was 17.1%, significantly higher than the 5.3% for paclitaxel alone, with a statistically significant p-value of 0.031 [12][13] Question: What is the rationale behind the DLL4 positive cancers basket study? - DLL4 notch signaling is involved in various malignancies, and the company aims to explore the efficacy of tevesimig in these cancers due to its demonstrated monotherapy activity [19] Question: What are the upcoming catalysts for the company? - Key upcoming catalysts include readouts from the tevesimig study, the initiation of several important clinical trials, and data from the CTX-471 basket study [34]

Compass Therapeutics (CMPX) 2025 Conference May 08, 2025 01:30 PM ET Speaker0 so we're gonna go ahead and get started on time. Again, welcome to the second day of the Citizens Life Science Conference. It's my pleasure to introduce the next presenting company which is Compass Therapeutics. Presenting for the company or having our discussion is Doctor. Tom Schutz, CEO of Compass. Welcome Tom, really appreciate your time. Speaker1 Thanks, Ren. Thanks for inviting us. Speaker0 So, you know, people in the audien ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Registrant's telephone number, including area code: (617) 500-8099 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-39696 COMPASS THERAPEUTICS ...

EXHIBIT 99.1 Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update BOSTON, May 08, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical- stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today reported first quarter 2025 financial results and provided a business update. "We're proud of the progress we've made this quarter, especially the achievement of the primary endpoint in our COMPANION ...

Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate (ORR), including one complete response, compared to a 5.3% ORR for paclitaxel alone, in patients with BTC treated in the second-line setting. First patient dosed and actively enrolling patients in an Investigator Sponsored Trial (IST) evaluating tovecimig in patients with BTC in the first-line setting.Successfull ...

BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical- stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation entitled "Enhanced Efficacy of CTX-471, A CD137 Agonist Antibody, In Models of Immune Checkpoint Failure Via Simultaneous Blockade of Neo-Angiogenesis" at the American Association for Cancer Research (AACR) Annual Meeting, from April 25–30, 2025, at the McCormick Place Co ...

Core Insights - Compass Therapeutics, Inc. has initiated an Investigator Sponsored Trial (IST) for tovecimig (CTX-009), a bispecific antibody targeting DLL4 and VEGF-A, in patients with biliary tract cancer (BTC) [1][2] - The trial is being conducted at The University of Texas MD Anderson Cancer Center and aims to evaluate the efficacy and safety of tovecimig in combination with standard first-line treatments [1][2] - The company has also reported that tovecimig met the primary endpoint in a separate Phase 2/3 study, with results for secondary endpoints expected in Q4 2025 [2] Company Overview - Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for oncology [4] - The company aims to target critical biological pathways involved in tumor growth and immune response, with a pipeline designed to address multiple human diseases [4] - Founded in 2014 and headquartered in Boston, Massachusetts, Compass Therapeutics is advancing its product candidates through clinical development [4] Product Information - Tovecimig is designed to block DLL4 and VEGF-A signaling pathways, which are essential for angiogenesis and tumor vascularization [3] - Preclinical and early clinical data suggest that tovecimig has shown robust anti-tumor activity across various solid tumors, including cholangiocarcinoma and pancreatic cancer [3] - The ongoing COMPANION-002 trial is evaluating tovecimig in combination with paclitaxel for previously treated advanced metastatic BTC [3] Trial Details - The IST will involve approximately 50 patients with unresectable or metastatic BTC, assessing safety and tolerability alongside a standard regimen of gemcitabine, cisplatin, and durvalumab [2] - The primary objectives include evaluating 6-month progression-free survival and determining the maximum tolerated dose of tovecimig [2] - Secondary objectives will assess overall response rate, duration of response, progression-free survival, and overall survival [2]

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Stifel 2025 Virtual Targeted Oncology Forum taking place April 8-9, 2025. Presentation Details Date: Tuesday, April 8, 2025 Time: 3:00 PM EDTWebcast Link: https://wsw.com/webcast/stifel99/cmpx/2119000 Virtual/Replay availabilit ...

BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, announced statistically significant top-line data on the primary efficacy endpoint for COMPANION-002, the Company's ongoing Phase 2/3 randomized trial of tovecimig (formerly CTX-009) in combination with paclitaxel in patients with advanced BTC. "We are thrilled to share these positive primary endpoint data from t ...